Assays

Assessing the safety and efficacy of biotherapeutics is imperative during the drug-development process. In particular, pharmacokinetic (PK) and anti-drug antibody (ADA) assays are conducted to study and evaluate new drug candidates and biosimilars. For PK/ADA assays, anti-idiotype antibodies (Anti-IDs) are powerful tools to measure the concentration of antibody drugs in patient samples and serve as […]

In this free TechNote by SAMDI Tech, learn how the company’s radioactivity assays overcome key challenges in drug discovery by offering key solutions, including: Detecting low amounts of product with sensitive assays Generating data rapidly with high-throughput, 384-well capabilities Characterising potent inhibitors by benefiting from lower enzyme concentrations Learn how SAMDI Tech’s radioactivity assay characterised […]

PerkinElmer has announced that the performance of its SARS-CoV-2 RT-PCR assays are not impacted by the emergence of Omicron (B.1.1.529), a variant of concern that was recently identified by the World Health Organization (WHO).  How the assays work  There are more than 30 Omicron mutations reported in the S gene of SARS-CoV-2. PerkinElmer’s assays do […]

A free webinar, Sensitive signature peptide quantification using accurate mass spectrometry, was hosted by DDW on December 1, 2021, at 4PM GMT, 9AM PT; 12PM ET; 5PM CET. It was supported by SCIEX.   Emerging advancements in protein biotherapeutics are driving the need for more sensitive and accurate bioanalytical methods for their quantification. Serving as an orthogonal technology to […]

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening.  Alain Parthoens, Ncardia’s Chairman, said: “Kiniciti is uniquely suited to help Ncardia expand globally and to […]

The importance of biotherapeutics as a class of drugs continues to increase. Indeed, their low toxicity and high specificity justify their investigation as drug candidates. Yet, quantification studies of biotherapies in complex biological matrices can be very challenging. In particular, high background noise and interferences due to endogenous proteins may compromise the assay. Dr. Xin Zhang, […]

Sensitive signature peptide quantification using accurate mass spectrometry is a free webinar that was hosted by DDW on December 1, 2021, at 4PM GMT, 9AM PT; 12PM ET; 5PM CET. It was supported by SCIEX.  Dr. Xin Zhang, Senior Application Scientist at SCIEX, presented an assay development method using accurate mass spectrometry to quantify a […]

A free webinar, Sensitive signature peptide quantification using accurate mass spectrometry, was hosted by DDW on December 1, 2021, at 4PM GMT, 9AM PT; 12PM ET; 5PM CET. It was supported by SCIEX.   Emerging advancements in protein biotherapeutics are driving the need for more sensitive and accurate bioanalytical methods for their quantification. Serving as an orthogonal technology to […]

SAGA Diagnostics, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with Astra Zeneca to develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies.   James Hadfield, Director Epigenomics, Oncology Translational Medicine, Oncology R&D, AstraZeneca, said: “We […]

The importance of biotherapeutics as a class of drugs continues to increase. Indeed, their low toxicity and high specificity justify their investigation as drug candidates. Yet, quantification studies of biotherapies in complex biological matrices can be very challenging. In particular, high background noise and interferences due to endogenous proteins may compromise the assay. Dr. Xin Zhang, […]